Fractyl Health, Inc. - Common Stock (GUTS)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) common stock between January 13, 2025 and January 29, 2026, inclusive (the “Class Period”). Fractyl Health, Inc. investors have until October 20, 2026 to file a lead plaintiff motion.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) common stock between January 13, 2025 and January 29, 2026, inclusive (the “Class Period”). Fractyl Health, Inc. investors have until October 20, 2026 to file a lead plaintiff motion.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) investors concerning the Company’s possible violations of the federal securities laws.

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS).

Law Offices of Howard G. Smith announces an investigation on behalf of Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026 (the "Class Period"). Fractyl is a metabolic therapeutics company that develops therapies for the treatment of type 2 diabetes (“T2D”) and obesity.

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita®. To register, click here.

One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance

BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.

BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences:

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure

Experienced market access leader joins to build reimbursement and health economic infrastructure for Revita® ahead of anticipated REMAIN-1 Pivotal Cohort topline data in early Q4 2026

Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita® in pivotal development for post-GLP-1 weight maintenance and Rejuva® entering first-in-human studies for type 2 diabetes

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m. ET.

Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m. ET.

Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (“Fractyl Health” or “the Company”) (NASDAQ: GUTS) for violations of the securities laws.

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (“Fractyl Health” or “the Company”) (NASDAQ: GUTS) for violations of the securities laws.

Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability

BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company’s executive leadership team and Board of Directors.

Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026